A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors
Status:
Recruiting
Trial end date:
2028-11-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety and tolerability of escalating
doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2
dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The
secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess
clinical activity of LP-284.